These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 10784550)

  • 1. How should cost data in pragmatic randomised trials be analysed?
    Thompson SG; Barber JA
    BMJ; 2000 Apr; 320(7243):1197-200. PubMed ID: 10784550
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized controlled trial and economic evaluation.
    Jain S; Arora NK
    Indian J Pediatr; 2000 May; 67(5):363-8. PubMed ID: 10885210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis and interpretation of cost data in randomised controlled trials: review of published studies.
    Barber JA; Thompson SG
    BMJ; 1998 Oct; 317(7167):1195-200. PubMed ID: 9794854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analyses of cost data in economic evaluations conducted alongside randomized controlled trials.
    Doshi JA; Glick HA; Polsky D
    Value Health; 2006; 9(5):334-40. PubMed ID: 16961551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost data for individual patients included in clinical studies: no amount of statistical analysis can compensate for inadequate costing methods.
    Graves N; Walker D; Raine R; Hutchings A; Roberts JA
    Health Econ; 2002 Dec; 11(8):735-9. PubMed ID: 12457373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unequal randomisation can improve the economic efficiency of clinical trials.
    Torgerson D; Campbell M
    J Health Serv Res Policy; 1997 Apr; 2(2):81-5. PubMed ID: 10180369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A framework for cost-effectiveness analysis from clinical trial data.
    O'Hagan A; Stevens JW
    Health Econ; 2001 Jun; 10(4):303-15. PubMed ID: 11400253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spinal cord stimulation versus reoperation for failed back surgery syndrome: a cost effectiveness and cost utility analysis based on a randomized, controlled trial.
    Wilkinson HA
    Neurosurgery; 2008 Aug; 63(2):E376; author reply E376. PubMed ID: 18797322
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficient use of endpoints in clinical trials: a clinical perspective.
    Terrin ML
    Stat Med; 1990; 9(1-2):155-60. PubMed ID: 2111931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic endpoints in clinical trials.
    Hlatky MA
    Epidemiol Rev; 2002; 24(1):80-4. PubMed ID: 12119860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are systematic reviews more cost-effective than randomised trials?
    Glasziou P; Djulbegovic B; Burls A
    Lancet; 2006 Jun; 367(9528):2057-8. PubMed ID: 16798380
    [No Abstract]   [Full Text] [Related]  

  • 12. Handling missing data in patient-level cost-effectiveness analysis alongside randomised clinical trials.
    Manca A; Palmer S
    Appl Health Econ Health Policy; 2005; 4(2):65-75. PubMed ID: 16162026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
    Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
    J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials.
    Taira DA; Seto TB; Siegrist R; Cosgrove R; Berezin R; Cohen DJ
    Am Heart J; 2003 Mar; 145(3):452-8. PubMed ID: 12660668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating incremental cost-effectiveness ratios and their confidence intervals with differentially censored data.
    Wang H; Zhao H
    Biometrics; 2006 Jun; 62(2):570-5. PubMed ID: 16918922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evaluation of different approaches to randomized clinical trials. Report on the 1987 MacArthur Foundation Network I Methodology Workshop.
    Kraemer HC; Pruyn JP
    Arch Gen Psychiatry; 1990 Dec; 47(12):1163-9. PubMed ID: 2147099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming the funding challenge: the cost of randomized controlled trials in the next decade.
    Shore BJ; Nasreddine AY; Kocher MS
    J Bone Joint Surg Am; 2012 Jul; 94 Suppl 1():101-6. PubMed ID: 22810458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trials and tribulations. Spiraling costs threaten gridlock.
    Malakoff D
    Science; 2008 Oct; 322(5899):210-3. PubMed ID: 18845742
    [No Abstract]   [Full Text] [Related]  

  • 19. Value of information analyses of economic randomized controlled trials: the treatment of intermittent claudication.
    Groot Koerkamp B; Spronk S; Stijnen T; Hunink MG
    Value Health; 2010; 13(2):242-50. PubMed ID: 19818058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conceptual issues in the analysis of cost data within cluster randomized trials.
    Flynn T; Peters T
    J Health Serv Res Policy; 2005 Apr; 10(2):97-102. PubMed ID: 15831192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.